title: Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.
abstract: BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melanoma and BRAF(V600) mutations. In order to evaluate BRAF tumor heterogeneity between primary and metastatic site, we have evaluated the performance of immunohistochemistry (IHC) with an anti-BRAF(V600E) antibody in both localization by comparison with high resolution melting analysis followed by Sanger sequencing in a parallel blinded study. A total of 230 samples distributed as primary melanoma (n = 88) and different types of metastatic samples (n = 142) were studied in 99 patients with advanced or metastatic melanoma (stage III or IV). The prevalence of each BRAF mutation was c.1799T>A, BRAF(V600E) (45.2%), c.1799_1800TG>AA, BRAF(V600E2) (3.0%), c.1798_1799GT>AA, BRAF(V600K) (3.0%), c.1801 A>G, BRAF(K601E) (1.3%), c.1789_1790CT>TC, BRAF(L597S) (0.4%), c.1780G>A, BRAF(D594N) (0.9%) respectively. IHC was positive in 109/112 samples harboring BRAF(V600E/E2) mutations and negative in other cases. The cytoplasmic staining was either strongly positive in tumor cells of BRAF(V600E) mutated cases. It appeared strong brown, different from the vesicular grey cytoplasmic pigmentation of melanophages. Concordance between the two techniques was 96.4%. Sensitivity of IHC for detecting the BRAF(V600E/E2) mutations was 97.3%, while specificity was 100%. Both our IHC and molecular study demonstrated homogeneity between primary and metastatic sites for BRAF status in melanoma. This study also provides evidence that IHC may be a cost-effective first-line method for BRAF(V600E) detection. Thereafter, molecular techniques should be used in negative, ambiguous or non-contributive cases.
authors: Department of Dermatology, CHU Bordeaux, Bordeaux, France.
authors: Lucile
authors: L
authors: Boursault
authors: Véronique
authors: V
authors: Haddad
authors: Béatrice
authors: B
authors: Vergier
authors: David
authors: D
authors: Cappellen
authors: Severine
authors: S
authors: Verdon
authors: Jean-Pierre
authors: JP
authors: Bellocq
authors: Thomas
authors: T
authors: Jouary
authors: Jean-Philippe
authors: JP
authors: Merlio
mesh_terms: D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry / Q000706:statistics & numerical data*; D008545:Melanoma / Q000175:diagnosis* / Q000235:genetics / Q000556:secondary; D009154:Mutation; D009367:Neoplasm Staging; D009691:Nucleic Acid Denaturation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012680:Sensitivity and Specificity; D017422:Sequence Analysis, DNA; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
references: Br J Dermatol. 2013 Feb;168(2):428-30
references: 22775439
references: N Engl J Med. 2011 Jun 30;364(26):2507-16
references: 21639808
references: Br J Dermatol. 2012 Nov;167(5):1124-30
references: 22759278
references: CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
references: 22700443
references: J Clin Oncol. 2000 Jan;18(1):158-66
references: 10623706
references: Am J Surg Pathol. 2013 Jan;37(1):61-5
references: 23026937
references: PLoS One. 2012;7(1):e29336
references: 22235286
references: Pathology. 2008 Apr;40(3):295-8
references: 18428050
references: Lancet. 2012 Jul 28;380(9839):358-65
references: 22735384
references: J Mol Diagn. 2013 Jan;15(1):70-80
references: 23159593
references: J Clin Oncol. 1999 Jul;17(7):2105-16
references: 10561265
references: Drug Des Devel Ther. 2012;6:391-405
references: 23251089
references: Arch Pathol Lab Med. 2012 Nov;136(11):1385-91
references: 22332713
references: N Engl J Med. 2012 Feb 23;366(8):707-14
references: 22356324
references: N Engl J Med. 2010 Aug 26;363(9):809-19
references: 20818844
references: Clin Cancer Res. 2007 Feb 1;13(3):806-15
references: 17289871
references: Acta Neuropathol. 2012 Feb;123(2):223-33
references: 22012135
references: N Engl J Med. 2012 Jul 12;367(2):107-14
references: 22663011
references: Curr Opin Oncol. 2008 Mar;20(2):183-9
references: 18300768
references: Mod Pathol. 2013 Mar;26(3):414-20
references: 23041829
references: Am J Surg Pathol. 2013 Mar;37(3):413-20
references: 23211290
references: Nat Genet. 2003 Jan;33(1):19-20
references: 12447372
references: Nature. 2010 Dec 16;468(7326):973-7
references: 21107323
references: J Am Acad Dermatol. 2012 Sep;67(3):488-91
references: 22890732
references: J Clin Oncol. 2012 Jul 10;30(20):2522-9
references: 22614978
references: J Invest Dermatol. 2003 Nov;121(5):1160-2
references: 14708620
references: Nature. 2011 Nov 23;480(7377):387-90
references: 22113612
references: Nature. 2002 Jun 27;417(6892):949-54
references: 12068308
references: J Clin Oncol. 2011 Apr 1;29(10):1239-46
references: 21343559
references: J Mol Diagn. 2007 Sep;9(4):464-71
references: 17690212
references: J Invest Dermatol. 2013 Apr;133(4):1027-33
references: 23096702
references: Eur J Cancer. 2013 Mar;49(5):1073-9
references: 23237741
references: Ann Oncol. 2013 Mar;24(3):742-8
references: 23131393
references: Nature. 2010 Mar 18;464(7287):431-5
references: 20130576
references: Semin Cutan Med Surg. 2012 Dec;31(4):267-73
references: 23174497
references: Am J Pathol. 2002 Jun;160(6):1967-72
references: 12057901
references: Br J Cancer. 2011 Feb 1;104(3):464-8
references: 21224857
references: J Mol Diagn. 2013 Jan;15(1):94-100
references: 23159108
references: J Clin Oncol. 1999 Sep;17(9):2745-51
references: 10561349
references: Cancer Discov. 2012 Sep;2(9):791-7
references: 22798288
references: Lancet Oncol. 2012 Nov;13(11):1087-95
references: 23051966
references: N Engl J Med. 2005 Nov 17;353(20):2135-47
references: 16291983
references: Acta Neuropathol. 2011 Jul;122(1):11-9
references: 21638088
references: J Transl Med. 2010 Jul 14;8:67
references: 20630094
references: J Mol Diagn. 2013 Jan;15(1):130-7
references: 23178437
references: Br J Dermatol. 2011 Apr;164(4):776-84
references: 21166657
references: N Engl J Med. 2012 Nov;367(18):1694-703
references: 23020132
references: Br J Cancer. 2013 Mar 5;108(4):924-31
references: 23403819